Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

Stopped Study terminated after assessment of potential benefit-risk from available data

Conditions

• Amyotrophic Lateral Sclerosis

Interventions

• DRUG: BLZ945

Sponsor

Novartis Pharmaceuticals